New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
07:14 EDTRHHBY, ABBV, PCYCAbbVie, Roche drug a real threat to Pharmacyclics, says Bernstein
After analyzing abstracts from the ASCO conference, Bernstein believes that ABT199, a treatment for CLL from Roche (RHHBY) and AbbVie (ABBV), is a "real threat" to Pharmacyclics' (PCYC) Imbruvica. However, the firm continues to believe that Imbruvica is impressive due to its duration of effect. It keeps an Outperform rating on Roche and a Market Perform rating on Pharmacyclics.
News For ABBV;RHHBY;PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 22, 2015
05:27 EDTRHHBYRoche sees FY15 core EPS to grow ahead of sales at constant exchange rates
Expects FY15 sales to grow low- to mid-single digit, at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.
05:27 EDTRHHBYRoche reports Q1 group sales CHF 11.83B vs. CHF 11.50B
Subscribe for More Information
April 21, 2015
07:06 EDTRHHBYBina Tech, AstraZeneca announce collaborative agreement for GMS
Bina Technologies, a member of the Roche Group (RHHBY), and AstraZeneca (AZN) announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Program and to further develop the Bina Genomic Management Solution. AstraZeneca will utilize the Bina GMS as an enterprise platform to support its development work across three main therapeutic areas: oncology, cardiovascular and metabolic disease, and respiratory, inflammation and autoimmunity. Bina’s proprietary technology enables translational and academic researchers to perform fast and scalable analyses to maximize the value of genomic data. Under the terms of the agreement, AstraZeneca will adopt Bina GMS globally to support enterprise genomic data analysis and management. Bina in turn will provide AstraZeneca with direct access to its scientific and engineering teams to further develop the Bina GMS for pharmaceutical applications.
05:33 EDTRHHBYInovio, Roche initiate clinical trial for DNA immunotherapy to treat HCB
Inovio Pharmaceuticals (INO) announced that it has initiated a Phase I trial to evaluate Inovio's DNA immunotherapy in patients who are chronically infected with hepatitis B. In 2013, Roche (RHHBY) and Inovio entered into a partnership to co-develop and commercialize Inovio's hepatitis B immunotherapy. This trial initiation triggers a $3M milestone payment from Roche to Inovio. This phase I, randomized, open-label, active-controlled, dose escalation study will evaluate the safety, tolerability, and immunogenicity of Inovio's hepatitis B immunotherapy, INO-1800, alone or in combination with INO-9112, Inovio's IL-12-based immune activator. This international study will enroll patients in the United States and Asia Pacific region with a primary endpoint of safety and tolerability of the therapy. The secondary endpoints will evaluate the cellular and humoral immune response to INO-1800 and investigate the therapy's effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care antiviral therapies.
April 20, 2015
14:32 EDTPCYC, ABBVPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information
09:05 EDTPCYCPharmacyclics reports positive data suggesting ibrutinib is an effective option
Ibrutinib data presented yesterday by Pharmacyclics at the American Association for Cancer Research, or AACR, Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft mice. These early, pre-clinical data show ibrutinib was associated with potent anti-fibrotic activity and longer survival in the treated mice. PDAC is a type of pancreatic cancer that is typically characterized by a fibro-inflammatory reaction, which makes PDAC a difficult disease to treat with current therapies. These data were also published in the April 15th edition of Cancer Research. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech.
08:47 EDTPCYCPharmacyclics announces positive results from PCYC-1102 study
Pharmacyclics announced that IMBRUVICA follow-up data in treatment-naive, or TN, and relapsed/refractory patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, or CLL and SLL respectively, demonstrated that, with up to 45 months of follow-up, the 94 patients who received IMBRUVICA 420 mg experienced a 91% overall response rate, or ORR, and 14% of all patients achieved a complete response. These data are an analysis of outcomes from the Phase I/IIb study, or PCYC-1102, and the ongoing extension study and were presented in an oral presentation at the American Association of Cancer Research.
07:20 EDTABBVAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:18 EDTABBVAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 17, 2015
16:50 EDTABBV, PCYCAbbVie extends exchange offer to acquire Pharmacyclics
Subscribe for More Information
05:32 EDTRHHBYAccelerate Diagnostics appoints Pete Bantock to Chief Culture Officer
Accelerate Diagnostics (AXDX) appointed Pete Bantock to the newly created position of Chief Culture Officer and Head of Human Resources. Bantock was most recently the SVP and Head of commercial Operations for the Americas. He will be replaced by Ron Price, who joins the company from Roche (RHHBY) where he held the position of VP of Point of Care and Commercial Operations.
April 16, 2015
08:04 EDTRHHBYRoche granted orphan status for lymphoma treatment
The FDA granted Roche's Genentech unit orphan status for Gazyva, its treatment of follicular lymphoma.
April 15, 2015
19:08 EDTABBVEnanta confirms AbbVie hepatitis C treatment granted priority review in Japan
Subscribe for More Information
19:03 EDTABBVAbbVie's chronic hepatitis C treatment granted priority review in Japan
Subscribe for More Information
April 14, 2015
06:30 EDTRHHBYRoche to seek to have cancer drug tested in 11 trials in 2015, Reuters says
Roche said it would seek to have its immunotherapy cancer drug, MPDL3280A, in 11 late stage trials by the end of 2015, aaccording to Reuters. The drug is being tested in melanoma, as well as lung, bladder, kidney, bowel and blood cancers, the news service noted. Reference Link
April 13, 2015
14:07 EDTABBV, PCYCEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
10:01 EDTRHHBYRoche acquires CAPP Medical
Roche announced it has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and industry veterans, to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA in blood.
10:00 EDTABBVOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:34 EDTABBVAbbVie upgraded on Imbruvica outlook at BMO Capital
Subscribe for More Information
07:02 EDTABBVAbbVie upgraded to Outperform from Market Perform at BMO Capital
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use